SC dismisses PIL seeking ban on Ranbaxy drugs in India
The Supreme Court On Tuesday Dismissed PIL Filed Against Ranbaxy For Allegedly Manufacturing And Selling Substandard Drugs In India. The Petitioner Has Failed To Bring In Evidence Against Ranbaxy, The Apex Court Said.
The Supreme Court on Tuesday dismissed PIL filed against Ranbaxy for allegedly manufacturing and selling substandard drugs in India. The petitioner has failed to bring in evidence against Ranbaxy, the apex court said.
The PIL alleged that the company has been fined USD 500 million by the US Food and Drug Administration (USFDA) for making and selling "adulterated" drugs. It also sought sealing of all its manufacturing units here, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.
The petitioner alleged that despite Ranbaxy pleading guilty to supplying adulterated drugs in the US and it being fined such a huge amount, the Centre has not taken any action to prohibit or ban the drugs made by the company.
He also sought action against Indian drug regulator, Central Drug Standards Control Organisation (CDSCO), for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA probe against the company.
For all the Latest India News, Download News Nation Android and iOS Mobile Apps.
More from India
Do You Know....Ambedkar as a Social Scientist?
10th anniversary of Crimea: A Photo Exhibition was organized at the Russian House in New Delhi
GATORADE USES DATA TO UNLOCK URBAN PLAYGROUNDS, WITH THEIR INITIATIVE 'TURF FINDER'
News Nation Network Receives Prestigious Amity Corporate Excellence Award at INBUSH ERA Global Summit
Foreign Ministers of Finland and India Unveil a Logo Marking 75 Years of Diplomatic Ties